Patent Assignment
Reel/Frame 071218/0445
Security Interest
Recorded: 2025-05-07
Pages: 25
Assignor
SAREPTA THERAPEUTICS, INC.
Executed: 2025-02-13
Assignee
JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
10 S. DEARBORN ST., L2, CHICAGO, ILLINOIS, 60603
Covered Properties
(147)
Multiple Exon Skipping Compositions for Dmd
Application:
18/778,132 →
Publication:
US US20250154507A1
Oligonucleotides for Treating Expanded Repeat Diseases
Application:
18/310,922 →
Publication:
US US20240209363A1
Compositions for Treating Muscular Dystrophy
Application:
18/541,286 →
Compositions for Treating Muscular Dystrophy
Application:
18/814,323 →
Publication:
US US20260117225A1
Compositions for Treating Muscular Dystrophy
Application:
18/966,357 →
Publication:
US US20260117227A1
Exon Skipping Compositions for Treating Muscular Dystrophy
Application:
18/885,116 →
Publication:
US US20250236869A1
Exon Skipping Compositions for Treating Muscular Dystrophy
Application:
18/885,088 →
Publication:
US US20250145991A1
Peptide Oligonucleotide Conjugates
Peptide Oligonucleotide Conjugates
Application:
19/029,784 →
Publication:
US US20260014263A1
Antisense-Induced Exon Exclusion in Type Vii Collagen
Application:
18/410,720 →
Publication:
US US20240415857A1
Modified Antisense Oligomers for Exon Inclusion in Spinal Muscular Atrophy
Application:
18/813,696 →
Publication:
US US20250241940A1
Peptide Oligonucleotide Conjugates
Application:
18/658,614 →
Publication:
US US20250057965A1
Processes for Preparing Phosphorodiamidate Morpholino Oligomers
Antisense Oligomers and Methods of Using the Same for Treating Diseases Associated with the Acid Alpha-Glucosidase Gene
Application:
18/910,901 →
Publication:
US US20250171779A1
Phosphorodiamidate Morpholino Oligomers
Exon Skipping Oligomer Conjugates for Muscular Dystrophy
Application:
18/181,271 →
Publication:
US US20230381216A1
Exon Skipping Oligomer Conjugates for Muscular Dystrophy
Exon Skipping Oligomer Conjugates for Muscular Dystrophy
Application:
18/807,055 →
Publication:
US US20250064959A1
Antisense Oligomer Compounds
Application:
18/145,604 →
Publication:
US US20230407301A1
Exon Skipping Oligomers for Muscular Dystrophy
Application:
16/973,464 →
Publication:
US US20220251551A1
Treatment Methods for Muscular Dystrophy
Exon Skipping Oligomers and Oligomer Conjugates for Muscular Dystrophy
Application:
18/634,360 →
Publication:
US US20250092393A1
Compositions for Treating Muscular Dystrophy
Application:
17/603,229 →
Publication:
US US20220193246A1
Exon Skipping Oligomers and Oligomer Conjugates for Muscular Dystrophy
Application:
18/440,684 →
Publication:
US US20250090569A1
Exon Skipping Oligomers for Muscular Dystrophy
Application:
18/484,970 →
Publication:
US US20240344067A1
Compositions Comprising Exon Skipping Oligonucleotide Conjugates for Treating Muscular Dystrophy
Application:
18/257,547 →
Publication:
US US20240327831A1
Exon Skipping Oligomer Conjugates for Muscular Dystrophy
Application:
18/744,061 →
Publication:
US US20250179487A1
Methods for Treating Muscular Dystrophy
Application:
17/618,100 →
Publication:
US US20220296633A1
Methods for Treating Muscular Dystrophy with Casimersen
Application:
17/441,620 →
Publication:
US US20220152086A1
Adeno-Associated Virus Antibodies and Fragments Thereof
Methods for Analyzing Aav Capsid Proteins
Methods of Treating Muscular Dystrophy
Application:
18/876,051 →
Publication:
US US20260002175A1
Systemic Delivery of Adeno-Associated Virus Vector Expressing Gamma-Sarcoglycan and the Treatment of Muscular Dystrophy
Application:
18/444,018 →
Publication:
US US20240374684A1
Phosphorodiamidate Morpholino Oligomer Conjugates
Application:
18/842,988 →
Publication:
US US20250195667A1
Suspension Mode Seed Train Development for Adherent Cells
Production of Recombinant Aav Vectors for Treating Muscular Dystrophy
Application:
18/562,148 →
Publication:
US US20250018059A1
Formulation of an Antisense Oligomer Conjugate
Application:
18/500,627 →
Publication:
US US20240218365A1
Antisense Oligonucleotides Having One or More Abasic Units
Application:
18/693,769 →
Publication:
US US20240425864A1
Recombinant Aav Vectors for Treating Muscular Dystrophy
Application:
63/509,221 →
Recombinant Aav Vectors for Treating Muscular Dystrophy
Application:
63/518,055 →
Genetic Constructs for Gene Editing
Application:
63/635,770 →
Genetic Constructs for Gene Editing
Application:
63/683,285 →
Treatment of Genetic Neurological Conditions with Genomic Editing
Application:
63/638,225 →
Muscle Tropic Raav
Application:
63/654,224 →
Muscle Tropic Raav
Application:
63/660,638 →
Antisense Oligomers for Treatment of Chronic Kidney Disease
Application:
18/647,899 →
Publication:
US US20250066776A1
Humanized Umod Mouse Model Generation, Characterization and Methods of Use
Application:
63/564,345 →
Dystrophin and Micro-Dystrophin Antibodies and Fragments Thereof
Application:
63/701,661 →
Dose Packaging System for Medication and Method of Storing Dose Therein
Aav Transfer Cassette
Adeno-Associated Virus Vectors for Treatment of Rett Syndrome
Application:
18/022,059 →
Publication:
US US20230304038A1
Adeno-Associated Virus Vectors for Treatment of Rett Syndrome
Application:
18/680,380 →
Publication:
US US20240392316A1
Raav Production Methods
Application:
63/448,872 →
Oligonucleotide Compound and Method for Treating Nidovirus Infections
ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ss/RNA VIRAL INFECTION
Antisense Antiviral Compounds and Methods for Treating a Filovirus Infection
Antisense Antiviral Compounds and Methods for Treating a Filovirus Infection
Antisense Antiviral Compounds and Methods for Treating a Filovirus Infection
Antisense Antiviral Compounds and Methods for Treating a Filovirus Infection
Antisense Antiviral Compounds and Methods for Treating a Filovirus Infection
Antisense Composition and Method for Treating Muscle Atrophy
Antisense Composition and Method for Treating Muscle Atrophy
Antisense Composition and Method for Treating Muscle Atrophy
Antisense Composition and Method for Treating Muscle Atrophy
Antisense Antibacterial Method and Compound
Antibacterial Antisense Oligonucleotide and Method
Antibacterial Antisense Oligonucleotide and Method
Antibacterial Antisense Oligonucleotide and Method
Antibacterial Antisense Oligonucleotide and Method
Antibacterial Antisense Oligonucleotide and Method
Oligonucleotide Analogs Having Cationic Intersubunit Linkages
Compound and Method for Treating Myotonic Dystrophy
Compound and Method for Treating Myotonic Dystrophy
Compound and Method for Treating Myotonic Dystrophy
Compound and Method for Treating Myotonic Dystrophy
Compound and Method for Treating Myotonic Dystrophy
Method of Synthesis of Morpholino Oligomers
Synthesis of Morpholino Oligomers Using Doubly Protected Guanine Morpholino Subunits
Multiple Exon Skipping Compositions for Dmd
Multiple Exon Skipping Compositions for Dmd
Multiple Exon Skipping Compositions for Dmd
Multiple Exon Skipping Compositions for Dmd
Multiple Exon Skipping Compositions for Dmd
Multiple Exon Skipping Compositions for Dmd
Multiple Exon Skipping Compositions for Dmd
Antisense Antiviral Compound and Method for Treating Influenza Viral Infection
Antisense Antiviral Compound and Method for Treating Influenza Viral Infection
Antisense Modulation of Interleukins 17 and 23 Signaling
Oligonucleotide Analogues Having Modified Intersubunit Linkages and/or Terminal Groups
Oligonucleotide Analogues Having Modified Intersubunit Linkages and/or Terminal Groups
Oligonucleotide Analogues Having Modified Intersubunit Linkages and/or Terminal Groups
Oligonucleotide Analogues Having Modified Intersubunit Linkages and/or Terminal Groups
dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
Dsrna Molecules Comprising Oligonucleotide Analogs Having Modified Intersubunit Linkages and/or Terminal Groups
Functionally-Modified Oligonucleotides and Subunits Thereof
Functionally-Modified Oligonucleotides and Subunits Thereof
Functionally-Modified Oligonucleotides and Subunits Thereof
Functionally-Modified Oligonucleotides And Subunits Thereof
Peptide Oligonucleotide Conjugates
Peptide Oligonucleotide Conjugates
Peptide Oligonucleotide Conjugates
Peptide Oligonucleotide Conjugates
Peptide Oligonucleotide Conjugates
Induced Exon Inclusion in Spinal Muscle Atrophy
Induced Exon Inclusion in Spinal Muscle Atrophy
Oligonucleotides for Treating Expanded Repeat Diseases
Oligonucleotides for Treating Expanded Repeat Diseases
Oligonucleotide Analogues Targeting Human Lmna
Oligonucleotide Analogues Targeting Human Lmna
Oligonucleotide Analogues Targeting Human Lmna
Oligonucleotide Analogues Targeting Human Lmna
Boronic Acid Conjugates of Oligonucleotide Analogues
Compositions for Treating Muscular Dystrophy
Compositions for Treating Muscular Dystrophy
Compositions for Treating Muscular Dystrophy
Exon Skipping Compositions for Treating Muscular Dystrophy
Exon Skipping Compositions for Treating Muscular Dystrophy
Exon Skipping Compositions for Treating Muscular Dystrophy
Antisense-Induced Exon Exclusion in Myostatin
Peptide Oligonucleotide Conjugates
Peptide Oligonucleotide Conjugates
Peptide Oligonucleotide Conjugates
Antisense-Induced Exon Exclusion in Type Vii Collagen
Antisense-Induced Exon Exclusion in Type Vii Collagen
Methods and Compounds for Treatment of Lymphocyte-Related Diseases and Conditions
Modified Antisense Oligomers for Exon Inclusion in Spinal Muscular Atrophy
Modified Antisense Oligomers for Exon Inclusion in Spinal Muscular Atrophy
Processes for Preparing Oligomers
Processes for Preparing Oligomers
Processes for Preparing Phosphorodiamidate Morpholino Oligomers
Antisense Oligomers and Methods of Using the Same for Treating Diseases Associated with the Acid Alpha-Glucosidase Gene
Antisense Oligomers and Methods of Using the Same for Treating Diseases Associated with the Acid Alpha-Glucosidase Gene
Processes for Preparing Phosphorodiamidate Morpholino Oligomers
Processes for Preparing Phosphorodiamidate Morpholino Oligomers
Exon Skipping Oligomer Conjugates for Muscular Dystrophy
Exon Skipping Oligomer Conjugates for Muscular Dystrophy
Exon Skipping Oligomer Conjugates for Muscular Dystrophy
Exon Skipping Oligomer Conjugates for Muscular Dystrophy
Exon Skipping Oligomer Conjugates for Muscular Dystrophy
Antisense Oligomer Compounds
Exon Skipping Oligomer Conjugates for Muscular Dystrophy
Exon Skipping Oligomer Conjugates for Muscular Dystrophy
Exon Skipping Oligomer Conjugates for Muscular Dystrophy
Exon Skipping Oligomer Conjugates for Muscular Dystrophy
Adeno-Associated Virus Antibodies, Fragments Thereof and Encoding Polynucleotides
Systemic Delivery of Adeno-Associated Virus Vector Expressing Gamma-Sarcoglycan and the Treatment of Muscular Dystrophy
Adeno-Associated Virus Vectors for Treatment of Rett Syndrome
Related Assignments
(24)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
May 26, 2021
From: CAI, BAOZHONG; MARTINI, MITCHELL; SHIMABUKU, ROSS; THOMAS, KATIE
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 056355/0521 →
Assignment of Assignor's Interest
Oct 6, 2023
From: HANSON, GUNNAR J.; ZHOU, MING
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 065148/0904 →
Assignment of Assignor's Interest
Oct 10, 2024
From: PASSINI, MARCO A.; HANSON, GUNNAR J.
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 068861/0823 →
Assignment of Assignor's Interest
Oct 23, 2024
From: RAKHADE, SANJAY; CHARLESTON, JAY
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 069233/0545 →
Assignment of Assignor's Interest
Jan 14, 2025
From: SUN, HUADONG; EAST, LILLY; TINSLEY, JON; ELKINS, JAKE
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 069865/0358 →
Assignment of Assignor's Interest
Feb 7, 2025
From: CAI, BAOZHONG; MARTINI, MITCHELL; THOMAS, KATIE; SHIMABUKU, ROSS
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 070154/0732 →
Assignment of Assignor's Interest
Feb 13, 2025
From: SCHNELL, FREDERICK JOSEPH; PASSINI, MARCO; ESTRELLA, NELSA; HANSON, GUNNAR
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 070206/0340 →
Assignment of Assignor's Interest
Feb 26, 2025
From: BESTWICK, RICHARD K.; FRANK, DIANE ELIZABETH
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 070331/0311 →
Change of Name
Feb 26, 2025
From: AVI BIOPHARMA, INC.
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 070330/0604 →
Assignment of Assignor's Interest
Feb 26, 2025
From: BESTWICK, RICHARD K.; FRANK, DIANE ELIZABETH; SCHNELL, FREDERICK JOSEPH
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 070330/0378 →
Assignment of Assignor's Interest
Feb 26, 2025
From: SAZANI, PETER; KOLE, RYSZARD
To: AVI BIOPHARMA, INC.
Reel/Frame 070330/0369 →
Assignment of Assignor's Interest
Feb 27, 2025
From: PASSINI, MARCO A.; HANSON, GUNNAR J.
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 070353/0157 →
Assignment of Assignor's Interest
Feb 27, 2025
From: SCHNELL, FREDERICK JOSEPH; WU, CHIA-LING
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 070353/0242 →
Assignment of Assignor's Interest
Mar 13, 2025
From: HANSON, GUNNAR J.; ZHOU, MING
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 070499/0383 →
Assignment of Assignor's Interest
Mar 14, 2025
From: SCHNELL, FREDERICK J.; CAI, BAOZHONG; GATLIN, JASON; IVERSEN, PATRICK L.
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 070523/0597 →
Assignment of Assignor's Interest
Apr 2, 2025
From: SCHNELL, FREDERICK J.; CAI, BAOZHONG; GATLIN, JASON; IVERSEN, PATRICK L.
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 070718/0690 →
Assignment of Assignor's Interest
Apr 7, 2025
From: SNEDEKER, JOHN; RODINO-KLAPAC, LOUISE; POTTER, RACHAEL
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 070752/0655 →
Assignment of Assignor's Interest
Apr 22, 2025
From: HANSON, GUNNAR J.; ZHOU, MING
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 070919/0492 →
Assignment of Assignor's Interest
Apr 22, 2025
From: LINSLEY, PETER; LEPPERT, BRIAN JAMES; HANSON, GUNNAR J.
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 070905/0743 →
Assignment of Assignor's Interest
May 27, 2025
From: KAYE, EDWARD M.
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 071393/0386 →
Assignment of Assignor's Interest
May 27, 2025
From: PASSINI, MARCO A.; HANSON, GUNNAR J
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 071393/0351 →
Assignment of Assignor's Interest
May 27, 2025
From: PASSINI, MARCO A.; HANSON, GUNNAR J.
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 071393/0347 →
Assignment of Assignor's Interest
May 27, 2025
From: KAYE, EDWARD M.
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 071221/0437 →
Assignment of Assignor's Interest
Feb 2, 2026
From: SCHNELL, FREDERICK JOSEPH
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 073653/0863 →